[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY37753A - Antagonistas de péptido pac1 - Google Patents

Antagonistas de péptido pac1

Info

Publication number
UY37753A
UY37753A UY0001037753A UY37753A UY37753A UY 37753 A UY37753 A UY 37753A UY 0001037753 A UY0001037753 A UY 0001037753A UY 37753 A UY37753 A UY 37753A UY 37753 A UY37753 A UY 37753A
Authority
UY
Uruguay
Prior art keywords
pac1
peptide antagonists
antagonists
peptides
migraine
Prior art date
Application number
UY0001037753A
Other languages
English (en)
Inventor
Chen Irwin
Chong Su
Essa Hu Harrington
Fang-Tsao Hong
Jason C Long
Leslie P Miranda
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY37753A publication Critical patent/UY37753A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se brindan péptidos novedosos que se enlazan a PAC1 humano. Estos péptidos que son antagonistas de PAC1 son útiles en varios trastornos relacionados con PAC1, que incluye el tratamiento /o la prevención de trastornos de cefalea, lo que incluye migraña, como ser migraña aguda.
UY0001037753A 2017-06-02 2018-05-31 Antagonistas de péptido pac1 UY37753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762514440P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
UY37753A true UY37753A (es) 2018-11-30

Family

ID=62685214

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037753A UY37753A (es) 2017-06-02 2018-05-31 Antagonistas de péptido pac1

Country Status (10)

Country Link
US (1) US11643440B2 (es)
EP (1) EP3630147A2 (es)
JP (1) JP7195281B2 (es)
AR (1) AR111842A1 (es)
AU (1) AU2018275270B2 (es)
CA (1) CA3065115A1 (es)
MA (1) MA48780A (es)
TW (1) TW201920235A (es)
UY (1) UY37753A (es)
WO (1) WO2018222991A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3990493A1 (en) 2019-06-28 2022-05-04 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
KR960705209A (ko) 1993-09-10 1996-10-09 잭 엠. 그랜노위츠 녹색 형광 단백의 용도
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JPH08333392A (ja) * 1995-06-05 1996-12-17 Shiseido Co Ltd 生理活性ポリペプチド類
US6462016B1 (en) * 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US20020182729A1 (en) * 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
CA2485216A1 (en) 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
ES2447843T3 (es) 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso
CN101125881A (zh) 2007-07-20 2008-02-20 暨南大学 重组pac1受体结抗剂d(25-44)rmmax及其表达方法与应用
WO2009033489A2 (en) 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
CA2730615A1 (en) 2008-07-18 2010-01-21 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
WO2010078469A2 (en) 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Sand fly salivary proteins as novel factor xa inhibitors and methods of use
JP5447784B2 (ja) 2009-03-12 2014-03-19 国立大学法人 鹿児島大学 マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same

Also Published As

Publication number Publication date
AU2018275270B2 (en) 2024-06-06
WO2018222991A3 (en) 2019-01-31
MA48780A (fr) 2020-04-08
TW201920235A (zh) 2019-06-01
JP2020522476A (ja) 2020-07-30
WO2018222991A2 (en) 2018-12-06
CA3065115A1 (en) 2018-12-06
AU2018275270A1 (en) 2019-12-12
US20210395313A1 (en) 2021-12-23
AR111842A1 (es) 2019-08-21
EP3630147A2 (en) 2020-04-08
JP7195281B2 (ja) 2022-12-23
US11643440B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA202092435A3 (ru) Моноклональные антитела против bcma
NZ738008A (en) Tigit-binding agents and uses thereof
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891397A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
DOP2018000284A (es) Anticuerpos antifactor de la coagulación xi
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018015410A (es) Esteres de oxaborol y sus usos.
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201992883A1 (ru) АНТИТЕЛА К TrkB
MX2017006692A (es) Trastornos neurodegenerativos.
UY37753A (es) Antagonistas de péptido pac1
MX2020006758A (es) Cemento de alumina.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
WO2016135462A8 (en) Treatment

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103